Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × cemiplimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 42 Melanoma 19 Neoplasms 14 Neoplasm Metastasis 14 Squamous Cell Carcinoma of Head and Neck 13 Skin Neoplasms 11 Lung Neoplasms 10 Carcinoma, Squamous Cell 8 Carcinoma, Renal Cell 8 Head and Neck Neoplasms 7 Urinary Bladder Neoplasms 6 Recurrence 6 Ovarian Neoplasms 6 Colorectal Neoplasms 5 Carcinoma, Merkel Cell 5 Carcinoma, Basal Cell 5 Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Multiple Myeloma 4 Colonic Neoplasms 4 Adenocarcinoma 4 Mycosis Fungoides 3 Glioblastoma 3 Fallopian Tube Neoplasms 3 Cutaneous Squamous Cell Carcinoma 3 Carcinoma, Hepatocellular 3 Carcinoma 3 Uveal Melanoma 2

Interventions

osimertinib 11 Pemetrexed 10 Carboplatin 10 aflutinib 8 Gefitinib 7 Drug Therapy 7 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06865339 2025-09-10

TRIPL

Albert Einstein College of Medicine

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡